ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BLRX BioLineRx Ltd

0.6599
0.0846 (14.71%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
BioLineRx Ltd NASDAQ:BLRX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.0846 14.71% 0.6599 0.60 0.62 0.6216 0.5528 0.5614 582,908 23:40:50

Report of Foreign Issuer (6-k)

28/05/2019 12:05pm

Edgar (US Regulatory)



 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May 2019
_______________________
 
BioLineRx Ltd.
(Translation of Registrant’s name into English)
_______________________
 
2 HaMa’ayan Street
Modi’in 7177871, Israel
 
(Address of Principal Executive Offices)
_______________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  
 
Form 20-F         Form 40-F
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: 
 
Yes          No
 

The Registrant announces that it will hold the 2019 Annual General Meeting of Shareholders on July 2, 2019 at 3:00 p.m. (Israel time) at the Registrant’s office, 2 HaMa’ayan Street, Modi’in, Israel. Attached hereto as Exhibits 1 and 2 are, respectively, the Notice of Annual General Meeting and Proxy Statement, and Proxy Card.
 
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  BioLineRx Ltd.  
       
 
By:
/s/ Philip Serlin  
    Philip Serlin  
    Chief Executive Officer  
Dated: May 28, 2019      
 

 

1 Year BioLineRx Chart

1 Year BioLineRx Chart

1 Month BioLineRx Chart

1 Month BioLineRx Chart

Your Recent History

Delayed Upgrade Clock